Finerenone Use in Chronic Kidney Disease

Introduction to Finerenone

Finerenone should not be used in patients with end-stage renal disease (ESRD), as the landmark trials specifically excluded patients with eGFR <25 mL/min/1.73 m², and there is no established dosing or safety data for this population 1, 2

Evidence Base and Trial Populations

The major finerenone trials (FIDELIO-DKD and FIGARO-DKD) that established its efficacy and safety profile had strict eGFR inclusion criteria, enrolling patients with eGFR ≥25 to <75 mL/min/1.73 m² and eGFR 25-90 mL/min/1.73 m², respectively 3, 1
These trials demonstrated significant cardiovascular and renal benefits, including a 36% reduction in progression to ESKD, but this evidence applies only to patients with CKD stages 2-4, not those already in ESRD 1, 2

Dosing Considerations

The approved dosing algorithm clarifies that finerenone is not intended for ESRD, with no dosing recommendations existing for eGFR <25 mL/min/1.73 m² 3
The lowest approved starting dose is 10 mg daily for patients with eGFR 25-60 mL/min/1.73 m² 1

Hyperkalemia Risk

Hyperkalemia is the primary safety concern with finerenone, occurring in 10.8% vs 5.3% with placebo in trial populations (eGFR ≥25 mL/min/1.73 m²) 1, 2

Appropriate Referral Threshold

The American Diabetes Association guidelines recommend nephrology referral when eGFR falls below 30 mL/min/1.73 m² (stage 4 CKD) for discussion of renal replacement therapy 4, 3

Clinical Algorithm for Finerenone Use

Consider finerenone if eGFR 25-90 mL/min/1.73 m², type 2 diabetes with albuminuria (UACR ≥30 mg/g), and potassium ≤4.8 mmol/L 1, 3
Do not initiate finerenone if eGFR <25 mL/min/1.73 m², patient is on dialysis or has ESRD, baseline potassium >4.8 mmol/L, or heart failure with reduced ejection fraction 3, 1, 2

Finerenone Dosing and Management in Impaired Renal Function

Initial Dosing and Patient Eligibility

For patients with impaired renal function and type 2 diabetes, the American Diabetes Association recommends starting finerenone at 10 mg once daily if eGFR is 25-60 mL/min/1.73 m², and 20 mg once daily if eGFR is >60 mL/min/1.73 m², with uptitration to 20 mg after 1 month if serum potassium remains ≤4.8 mmol/L 5, 6
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that finerenone should only be initiated in patients with type 2 diabetes and chronic kidney disease who have albuminuria (UACR ≥30 mg/g) despite standard care, and are already on the maximum tolerated dose of RAS inhibitor (ACE inhibitor or ARB) 5, 6, 7

Potassium Monitoring and Dose Uptitration

The American Heart Association recommends verifying that serum potassium meets safety thresholds (≤4.8 mmol/L) before starting finerenone, and monitoring potassium levels regularly throughout treatment 5, 6, 7
The European Renal Association suggests uptitrating finerenone from 10 mg to 20 mg daily after 1 month of treatment if serum potassium remains ≤4.8 mmol/L, eGFR is stable, and the medication is well-tolerated 8, 7

Ongoing Management and Safety Considerations

The National Kidney Foundation recommends continuing finerenone if potassium remains ≤5.5 mmol/L, withholding finerenone if potassium rises >5.5 mmol/L, and restarting at 10 mg daily when potassium returns to ≤5.0 mmol/L 5, 6
The American College of Cardiology suggests that hyperkalemia is the primary safety concern with finerenone, but discontinuation rates remain low, with 2.3% of finerenone patients discontinuing due to hyperkalemia in the FIDELIO-DKD trial 8, 7

Initiation of Finerenone in CKD and Type 2 Diabetes

Patient Selection and Treatment Criteria

The American Journal of Kidney Diseases recommends initiating finerenone in adults with type 2 diabetes who have persistent albuminuria (≥30 mg/g) despite maximum tolerated RAS inhibitor therapy, eGFR ≥25 mL/min/1.73 m², and normal serum potassium (≤4.8 mmol/L) 9, 10
Patients with type 2 diabetes and chronic kidney disease should be considered for finerenone initiation, according to the American Journal of Kidney Diseases 9
The American Journal of Kidney Diseases suggests that patients with persistent albuminuria despite standard-of-care therapies are at high risk for CKD progression and cardiovascular events, supporting finerenone initiation 9

Treatment Sequencing and Dosing

The American Journal of Kidney Diseases recommends starting with a RAS inhibitor (ACE inhibitor or ARB) at maximum tolerated dose as first-line foundation therapy 9, 10
The American Journal of Kidney Diseases suggests that an SGLT2 inhibitor should be prioritized over finerenone as the next step after RAS inhibitor due to larger effects on reducing kidney and cardiovascular outcomes 9, 10
Finerenone may be considered in patients with SGLT2 inhibitor intolerance or persistent albuminuria despite SGLT2 inhibitor, according to the American Journal of Kidney Diseases 9, 10

Monitoring and Safety Considerations

The American Journal of Kidney Diseases recommends verifying serum potassium ≤4.8 mmol/L before starting finerenone and monitoring serum potassium regularly after initiation 9, 10
The American Journal of Kidney Diseases suggests that finerenone should not be initiated in patients who have not been optimized on maximum tolerated RAS inhibitor first 9, 10
Potassium monitoring is essential when using finerenone, as hyperkalemia can occur, although finerenone has a lower risk than steroidal MRAs, according to the American Journal of Kidney Diseases 9

Mineralocorticoid Receptor Antagonist Selection for Patients with Type 2 Diabetes and Chronic Kidney Disease

Introduction to Finerenone

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guideline recommends finerenone for patients with type 2 diabetes and chronic kidney disease, offering superior safety with significantly lower hyperkalemia risk compared to spironolactone while providing equivalent or superior cardiovascular and renal protection 11

Clinical Considerations for Finerenone Use

The American College of Cardiology recommends considering finerenone for patients with type 2 diabetes with CKD (eGFR 25-90 mL/min/1.73 m²) and albuminuria (UACR ≥30 mg/g) who are already on maximum tolerated RAS inhibitor (ACE-I or ARB) 11
Finerenone is preferred for patients with CKD with higher hyperkalemia risk due to its safer profile 11

Treatment Sequencing and Monitoring

The KDIGO 2022 guideline recommends a treatment sequence of RAS inhibitor (ACE-I or ARB) at maximum tolerated dose, followed by SGLT2 inhibitor, and then finerenone if persistent albuminuria despite above, or SGLT2i intolerance 11
Regular potassium monitoring is required after starting finerenone, with withholding if potassium >5.5 mmol/L and restarting at lower dose when potassium returns to ≤5.0 mmol/L 11

Finerenone Therapy for Type 2 Diabetes and Chronic Kidney Disease

Introduction to Finerenone Benefits

Finerenone is indicated for patients with type 2 diabetes and chronic kidney disease (CKD stages 2-4 with eGFR 25-90 mL/min/1.73 m²) who have persistent albuminuria (UACR ≥30 mg/g) despite maximum tolerated RAS inhibitor therapy, providing significant reductions in both cardiovascular events and kidney disease progression 12

Expected Cardiovascular and Kidney Benefits

The American College of Cardiology recommends finerenone for patients with type 2 diabetes and CKD, as it delivers a 13% reduction in composite cardiovascular outcomes (cardiovascular death, nonfatal MI, nonfatal stroke, or heart failure hospitalization) with HR 0.87 (95% CI 0.76-0.98) 12
Finerenone provides a prevention of progression from asymptomatic stage A heart failure to symptomatic incident heart failure, as demonstrated in the FIGARO-DKD trial with 7,437 patients over a median follow-up of 3.0 years 12
The kidney benefits of finerenone were established in the FIDELIO-DKD trial, which specifically enrolled patients with more advanced diabetic kidney disease, providing a 36% reduction in end-stage kidney disease with HR 0.64 (95% CI 0.41-0.995) 12

Clinical Context and Positioning

Finerenone is now incorporated into major guidelines including KDIGO 2022, American Diabetes Association 2024, and American College of Cardiology recommendations as add-on therapy for patients with persistent albuminuria despite standard care 12

Serum Potassium Monitoring for Patients on Finerenone

Introduction to Finerenone Therapy

The American College of Cardiology recommends monitoring serum potassium at 1 month after finerenone initiation, then every 4 months during maintenance therapy, with specific management thresholds at ≤4.8 mmol/L for continuation, 4.9-5.5 mmol/L for continued monitoring, and >5.5 mmol/L for temporary drug discontinuation 13, 14, 15

Pre-Initiation Requirements

Before starting finerenone, verify that serum potassium is ≤4.8 mmol/L, as patients with higher baseline potassium should not initiate therapy due to excessive hyperkalemia risk 13, 14, 15

Initial Monitoring Phase

Check serum potassium at 1 month after starting finerenone to capture the predictable initial rise in potassium that occurs with mineralocorticoid receptor antagonism 13, 14, 15

Maintenance Monitoring Schedule

Monitor serum potassium every 4 months during ongoing therapy to allow early detection of hyperkalemia while minimizing unnecessary testing burden 13, 14, 15

Potassium-Based Management Algorithm

For potassium ≤4.8 mmol/L, continue current finerenone dose (10 mg or 20 mg daily) and continue monitoring every 4 months 13, 14, 15
For potassium 4.9-5.5 mmol/L, continue finerenone at current dose without adjustment and maintain monitoring every 4 months 13, 14, 15
For potassium >5.5 mmol/L, immediately hold finerenone, evaluate and adjust dietary potassium intake, review concomitant medications that may contribute to hyperkalemia, and recheck potassium levels to confirm downtrend 13, 14, 15
Restart finerenone at 10 mg daily when potassium returns to ≤5.0 mmol/L 13, 14, 15

Clinical Context and Risk Factors

Independent risk factors for hyperkalemia include lower eGFR (particularly <45 mL/min/1.73 m²) 15 and beta-blocker use 14
Protective factors that reduce hyperkalemia risk include SGLT2 inhibitor co-administration 15

Important Monitoring Considerations

Be aware that potassium measurements have inherent variability due to diurnal and seasonal variation, plasma versus serum sampling differences, and medication effects 13, 14, 15
When interpreting borderline values, consider repeating the measurement before making treatment decisions 13, 14, 15

Common Pitfalls to Avoid

Do not permanently discontinue finerenone for a single episode of potassium >5.5 mmol/L unless other interventions fail 13, 14, 15
Temporary interruption with dose reduction upon restart (10 mg daily) successfully manages most cases 13, 14, 15

Proteinuria Management with Finerenone

Introduction to Finerenone

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines recommend a treatment hierarchy for diabetic kidney disease management, with finerenone as a third-line consideration for patients with persistent albuminuria despite SGLT2 inhibitor or SGLT2i intolerance 16

Patient Selection and Treatment Sequencing

Initiate finerenone in adults with type 2 diabetes who have persistent albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g) despite maximum tolerated renin-angiotensin-aldosterone system (RAS) inhibitor therapy, estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m², and serum potassium ≤4.8 mmol/L 16
The American College of Cardiology recommends a first-line foundation of maximum tolerated dose of ACE inhibitor or ARB, second-line priority of SGLT2 inhibitor, and third-line consideration of finerenone for patients with persistent albuminuria despite SGLT2 inhibitor or SGLT2i intolerance 16

Clinical Benefits

Finerenone provides substantial cardiorenal protection beyond proteinuria reduction, with a 36% reduction in progression to end-stage kidney disease (hazard ratio 0.64, 95% confidence interval 0.41-0.995) 16
Finerenone reduces composite cardiovascular outcomes (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, heart failure hospitalization) by 14% (hazard ratio 0.86, 95% confidence interval 0.78-0.95) 16
Finerenone reduces kidney composite outcomes (kidney failure, sustained ≥40% eGFR decrease, or kidney death) by 18% (hazard ratio 0.82, 95% confidence interval 0.73-0.93) 16

Safety Profile

Hyperkalemia occurred in 14% of patients with finerenone versus 6.9% with placebo in pooled trial data, with permanent discontinuation due to hyperkalemia rare (1.7% vs 0.6% placebo) and no deaths from hyperkalemia over 3 years 16

Finerenone Initiation and Dosing in Diabetic Kidney Disease

Patient Selection

Adults with type 2 diabetes and persistent albuminuria (UACR ≥ 30 mg/g) despite maximally tolerated ACE‑inhibitor or ARB therapy are eligible for finerenone 17.
Eligible kidney function: estimated GFR ≥ 25 mL/min/1.73 m² (CKD stages 2–4) 17.
Baseline serum potassium must be ≤ 4.8 mmol/L before starting therapy [17][18].

Initiation Dosing Protocol

eGFR 25–60 mL/min/1.73 m²: start finerenone 10 mg once daily [17][18]19.
eGFR > 60 mL/min/1.73 m²: start finerenone 20 mg once daily [17][18]19.
This eGFR‑based dosing was applied in the phase‑3 FIDELIO‑DKD and FIGARO‑DKD trials to balance efficacy with hyperkalaemia risk [17][18].

Dose Titration Strategy

After 1 month of treatment, increase the dose from 10 mg to 20 mg daily if:
- Serum potassium remains ≤ 4.8 mmol/L [17][18]19; and
- eGFR is stable (no clinically significant decline) [17][18].
The 1‑month interval captures the predictable early rise in potassium associated with mineralocorticoid‑receptor antagonism.

Potassium Monitoring

Pre‑initiation: confirm serum potassium ≤ 4.8 mmol/L 17.
Initial monitoring: check potassium at 1 month after starting finerenone.
Ongoing monitoring: measure serum potassium every 4 months during continued therapy.

Additional Monitoring Parameters

eGFR: assess at baseline, 1 month, then every 4 months to ensure renal stability.
UACR: obtain at baseline and at month 4 to evaluate albuminuria response 17.

Clinical Efficacy (Phase‑3 Evidence)

Finerenone reduced the composite kidney outcome (kidney failure, ≥57 % eGFR decline, or renal death) by 23 % in the pooled FIDELITY analysis 17.
The same pooled analysis showed a 14 % reduction in the composite cardiovascular outcome (cardiovascular death, non‑fatal MI, non‑fatal stroke, or heart‑failure hospitalization) 17.
In the FIDELIO‑DKD trial, finerenone lowered the risk of progression to end‑stage kidney disease by 36 % 17.

Contraindications

Absolute:
- eGFR < 25 mL/min/1.73 m² or end‑stage renal disease (no established dosing or safety data).
- Baseline serum potassium > 4.8 mmol/L 17.
Relative (trial exclusion criteria):
- Heart failure with reduced ejection fraction (excluded from FIGARO‑DKD) 19.
- Uncontrolled hypertension (excluded from FIGARO‑DKD) 19.

Management of Finerenone‑Associated Serum Creatinine Increases

Expected Hemodynamic Effects

A rise in serum creatinine of up to 30 % from baseline after starting finerenone is an anticipated hemodynamic effect rather than acute kidney injury; therapy may be continued provided serum potassium stays ≤ 5.5 mmol/L. 20
Finerenone produces an acute eGFR decline of ≈ 2.9 mL/min/1.73 m² during the first 3 months, reflecting reduced intraglomerular pressure and not true renal injury. 20
This early eGFR/creatinine pattern mirrors that seen with ACE‑inhibitors and ARBs, where creatinine elevations up to 30 % are expected and do not signify AKI. 20
In the ACCORD BP trial, participants who experienced up to a 30 % creatinine increase from intensive blood‑pressure lowering showed no rise in mortality or progressive kidney disease, and kidney‑injury biomarkers were unchanged. 20

When to Continue Finerenone

Continue finerenone if the serum creatinine rise is < 30 % from baseline. 20
Continue when no evidence of volume depletion or exposure to nephrotoxic agents (e.g., NSAIDs, iodinated contrast, aminoglycosides) is present. 20
Continue if the patient is clinically stable without acute illness (e.g., infection, hospitalization). 20

When to Hold or Adjust Finerenone

Temporarily hold finerenone if the serum creatinine increase exceeds 30 % from baseline. 20
Hold when volume depletion, hypotension, or any acute illness is identified. 20
Hold if the patient has recent exposure to nephrotoxins such as NSAIDs, iodinated contrast, or aminoglycosides. 20

Safety Profile and Renal Outcomes

Non‑steroidal mineralocorticoid receptor antagonists (including finerenone) do not increase the risk of acute kidney injury when used appropriately. 20
The creatinine rise with finerenone reflects beneficial hemodynamic reduction of intraglomerular pressure, not tubular damage. 20

Practical Clinical Recommendations

Do not discontinue finerenone for modest creatinine elevations < 30 % (the pattern aligns with that of RAS inhibitors and supports long‑term kidney protection). 20
Do not mistake hemodynamic creatinine changes for AKI; the absence of volume depletion, nephrotoxin exposure, and clinical instability argues against true AKI. 20
Do not underdose finerenone out of fear of creatinine rise; pivotal trials used the maximally tolerated dose (10–20 mg daily, adjusted for eGFR). 20

Referral to Nephrology

Refer a patient to nephrology when a creatinine rise > 30 % from baseline fails to stabilize after holding potential offending agents. 20

Initiation and Management of Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease

Eligibility Criteria

Finerenone is FDA‑approved only for adults with type 2 diabetes and chronic kidney disease (CKD); it is not indicated for non‑diabetic CKD【21】.
Patients must have persistent albuminuria (UACR ≥ 30 mg/g) despite maximally tolerated renin‑angiotensin system (RAS) inhibition【22】【23】【21】.
Baseline estimated glomerular filtration rate (eGFR) must be ≥ 25 mL/min/1.73 m²; the example patient (eGFR 40) meets this threshold【22】【21】.
Baseline serum potassium must be ≤ 4.8 mmol/L before starting finerenone【22】【21】.
The patient must already be on a maximally tolerated dose of an ACE inhibitor or ARB【22】【23】.

Guideline Recommendations

KDIGO (2022) and ADA (2024) clinical practice guidelines give a strong recommendation for adding finerenone to patients with type 2 diabetes, CKD, and persistent albuminuria, independent of heart‑failure status【22】【23】【21】.
The DCRM 2.0 (2024) guideline specifically recommends finerenone for patients with HFpEF (EF ≥ 50 %) or HFmrEF (EF 41‑49 %) who also have CKD【24】.

Treatment Sequencing in Diabetic CKD

First‑line foundation: maximally tolerated ACE inhibitor or ARB【22】【23】.
Second‑line priority: an SGLT2 inhibitor, because it provides the largest effect on renal and cardiovascular outcomes【22】【23】【24】.
Third‑line consideration: finerenone for patients with persistent albuminuria despite ACE/ARB + SGLT2i, or when SGLT2i is contraindicated/intolerant【22】【23】.

Dosing and Titration Protocol

Initiation: start finerenone 10 mg once daily when eGFR is 25‑60 mL/min/1.73 m² (the patient’s eGFR 40 qualifies)【22】【21】.
Titration after 1 month: increase to 20 mg daily if serum potassium remains ≤ 4.8 mmol/L, eGFR is stable (no clinically significant decline), and the medication is well tolerated【22】【21】.

Expected Clinical Benefits (Evidence from Trials)

Kidney protection: finerenone reduced the composite kidney outcome (kidney failure, sustained ≥ 40 % eGFR decline, or kidney death) by 18 %【21】.
Progression to end‑stage kidney disease: risk lowered by 36 %【21】.
Cardiovascular protection: finerenone lowered the composite cardiovascular endpoint (CV death, non‑fatal MI, non‑fatal stroke, or HF hospitalization) by 14 %【21】.

Referral to Nephrology (Guideline‑Based Triggers)

Refer when eGFR falls below 30 mL/min/1.73 m² (stage 4 CKD) to discuss renal replacement options【21】.
Refer if a creatinine rise > 30 % from baseline persists despite holding potential offending agents【21】.
Refer for persistent hyperkalemia despite dietary and medication adjustments, or when the etiology of kidney disease is uncertain【21】.

Finerenone for Dual Cardiorenal Protection in Type 2 Diabetes with CKD (KDIGO 2022)

Efficacy

In the pooled FIDELITY analysis of patients with type 2 diabetes and CKD stage 3–4, finerenone reduced the composite kidney outcome (kidney failure, ≥57 % eGFR decline, or renal death) by 23 % (hazard ratio 0.77, 95 % CI 0.67–0.88)【25】.
In the FIDELIO‑DKD trial, finerenone lowered the risk of the composite kidney outcome (kidney failure, ≥40 % eGFR decline, or kidney death) by 18 % (hazard ratio 0.82, 95 % CI 0.73–0.93)【26】【25】.
Across the FIDELITY population (median eGFR 57.6 mL/min/1.73 m²; 67 % with severe albuminuria, ACR ≥300 mg/g), finerenone achieved a 14 % relative reduction in major cardiovascular events (cardiovascular death, non‑fatal MI, non‑fatal stroke, or hospitalization for heart failure) (hazard ratio 0.86, 95 % CI 0.78–0.95)【25】.

Evidence strength: derived from large, randomized, phase 3 trials (FIDELIO‑DKD, FIGARO‑DKD) and the pooled FIDELITY analysis, providing high‑quality RCT evidence.

Safety

Hyperkalemia (serum K⁺ > 5.5 mmol/L) occurred in 14 % of finerenone‑treated participants versus 6.9 % with placebo; permanent discontinuation due to hyperkalemia was rare (1.7 % vs 0.6 % over 3 years)【25】.

Evidence strength: safety data reported from the same phase 3 trial program, representing robust trial‑based safety profiling.

Baseline Requirements & Monitoring (KDIGO 2022)

Prior to initiating finerenone, patients must have serum potassium ≤ 4.8 mmol/L and be on a maximally tolerated ACE inhibitor or ARB【26】.
Persistent albuminuria (UACR ≥ 30 mg/g) despite optimal RAS blockade is a prerequisite for adding finerenone【26】.

Evidence strength: guideline‑based criteria drawn from KDIGO 2022 recommendations, which are grounded in the trial evidence above.

Treatment Sequencing (KDIGO 2022)

KDIGO recommends a hierarchical approach:

Evidence strength: guideline hierarchy reflects integration of multiple phase 3 trial results (including finerenone) and consensus expert appraisal.

Finerenone Initiation in Type 2 Diabetes with CKD and Heart‑Failure Risk

Eligibility Criteria

Patients with type 2 diabetes and chronic kidney disease stages 2–4 (estimated GFR 25–90 mL/min/1.73 m²) are eligible for finerenone therapy. 27
Persistent albuminuria (urine albumin‑to‑creatinine ratio ≥ 30 mg/g) despite maximally tolerated renin‑angiotensin system inhibition (ACE inhibitor or ARB) is required before adding finerenone. 27
Baseline serum potassium must be ≤ 4.8 mmol/L prior to initiation; this threshold also serves as an absolute contraindication if exceeded. 27
Patients must already be receiving the maximum tolerated dose of an ACE inhibitor or ARB as foundation therapy. 27

Guideline Recommendation

The KDIGO 2024 and ADA 2024 guidelines issue a strong recommendation (Grade 2A) for adding finerenone in the above clinical scenario, irrespective of the presence or absence of overt heart failure. 27

Treatment Sequencing (Cardiorenal Algorithm)

First‑line: Optimize ACE inhibitor or ARB dose to the maximum tolerated amount. 27
Second‑line: Add an SGLT2 inhibitor, which provides the greatest incremental cardiorenal benefit. 27
Third‑line: Introduce finerenone when albuminuria remains elevated despite SGLT2‑inhibitor therapy, or when an SGLT2 inhibitor is contraindicated or not tolerated. 27